Aptorum Group Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APM research report →
About the company
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections.
- CEO
- Ian Huen
- IPO
- 2018
- Employees
- 1
- HQ
- London, GB
Price Chart
- Market Cap
- $5.09M
- P/E
- -4.32
- P/S
- 0.00
- P/B
- 0.26
- EV/EBITDA
- -2.80
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -5.90%
- ROIC
- -10.36%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,363,270 · 68.06%
- EPS
- $-0.19 · 75.64%
- Op Income
- $-1,817,528
- FCF YoY
- -54.14%
- 52W High
- $4.47
- 52W Low
- $0.65
- 50D MA
- $0.88
- 200D MA
- $1.13
- Beta
- 0.17
- Avg Volume
- 134.38K
Get TickerSpark's AI analysis on APM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our APM coverage
Recent articles, reports, and earnings notes.
No research on APM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APM report →Similar companies
Peers in the same neighborhood.